SSKN (strataskinsciences.com) Short-Term Debt to Capital

STRATA Skin Sciences (SSKN) revenues rely on demand for laser therapy for vitiligo and psoriasis, which is driven by insurance coverage and US consumer confidence. The stock price trend demonstrates the 1.89 indicator. The business procures emitters from partners while maintaining control over software and product quality. Simultaneously, the company ensures personnel balance by adding regional managers to a strong engineering team.

This short-term debt-to-equity ratio measures the extent to which operations depend on short-term borrowings, reflecting the financial stability of the balance sheet structure. For STRATA Skin Sciences (SSKN), with its recurring payment model for consumables, this chart verifies the ability to generate internal cash flow, minimizing the need for expensive short-term lending to maintain leadership in dermatology.